Identification of a Transcription Factor Signature That Can Predict Breast Cancer Survival

Table 1

The Cox regression analysis of the association between clinicopathological factors (including risk scores) and the disease-free survival of BRCA patients.

Variables	Group	Patients ()	Univariate analysis		Patients ()	Multivariate analysis
			HR (95% CI)			HR (95% CI)
TCGA
Risk score	Low/high	475/475	4.18 (2.50-6.97)		418/411	4.40 (2.31-8.39)
Age	≤50/>50	290/660	0.67 (0.43-1.03)		251/578	0.66 (0.39-1.11)
Pathologic stage	I-II/III-IV	723/216	3.34 (2.15-5.19)		645/184	4.28 (2.49-7.34)
ER status	N/P	214/697	0.49 (0.31-0.77)		191/638	1.35 (0.32-5.61)
PR status	N/P	304/604	0.46 (0.30-0.71)		274/555	0.56 (0.26-1.19)
HER2 status	N/P	680/160	0.93 (0.47-1.82)		671/158	0.72 (0.30-1.69)
Triple negative	No/yes	804/146	1.62 (0.97-2.71)		685/144	1.89 (0.43-8.35)
GSE20685
Risk score	Low/high	164/163	2.41 (1.58-3.68)		164/158	2.22 (1.43-3.43)
Age	≤50/>50	209/118	0.74 (0.48-1.14)		206/116	0.79 (0.49-1.27)
T stage	I-II/III-IV	101/188	1.93 (1.50-2.49)		100/186	1.22 (0.86-1.74)
N stage	N0/N1-3	137/190	3.73 (2.26-6.15)		135/187	3.46 (1.99-6.01)
M stage	M0/M1	319/8	21.96 (10.49-45.99)		315/7	5.78 (2.02-16.58)
Adjacent CT	No/yes	54/268	2.07 (1.07-3.99)		54/268	1.34 (0.65-2.76)
GSE21653
Risk score	Low/high	126/126	2.83 (1.77-4.53)		115/113	3.04 (1.80-5.11)
Age	≤50/>50	92/160	1.14 (0.72-1.79)		81/147	1.31 (0.79-2.17)
T stage	I-II/III-IV	178/66	1.70 (1.06-2.73)		164/64	1.20 (0.72-2.01)
N stage	N0/N1-3	116/133	1.54 (0.98-2.40)		105/123	1.61 (0.97-2.69)
ER status	N/P	110/140	0.66 (0.43-1.02)		100/128	0.46 (0.17-1.26)
PR status	N/P	124/126	0.84 (0.55-1.30)		114/114	1.43 (0.60-3.38)
HER2 status	N/P	207/26	1.59 (0.84-3.03)		204/24	1.09 (0.42-2.85)
Triple negative	No/yes	160/85	1.19 (0.74-1.89)		145/83	0.88 (0.26-2.90)
GSE42568
Risk score	Low/high	52/52	3.68 (1.97-6.88)		51/50	4.18 (2.13-8.17)
Age	≤50/>50	27/77	0.66 (0.36-1.21)		25/76	0.72 (0.36-1.46)
N stage	N0/N1-3	45/59	4.35 (2.16-8.76)		44/57	4.72 (2.24-9.95)
ER status	N/P	34/67	0.44 (0.24-0.79)		34/67	0.40 (0.21-0.77)

HR: hazard ratio; CI: confidence interval; ER: estrogen receptor; PR: progesterone receptor; HER2/erbb2: epidermal growth factor receptor 2; Adjacent CT: adjacent chemotherapy; N: negative; P: positive.